DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/zgj8jz/preeclampsia) has announced the addition of the "Pre-Eclampsia - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Pre-Eclampsia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pre-Eclampsia and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- A1M Pharma AB
- Alnylam Pharmaceuticals, Inc.
- Glenveigh Medical, LLC
- Pluristem Therapeutics Inc.
- rEVO Biologics
- VG Life Sciences, Inc.
- antithrombin alfa (recombinant)
- digoxin immune fab
- Monoclonal Antibodies for Cardiovascular Diseases
- Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction
- Stem Cell Therapy for Pre-Eclampsia
For more information visit http://www.researchandmarkets.com/research/zgj8jz/preeclampsia